Prothrombin Complex Concentrate (PCC) Market Size, Share and Industry Analysis By Product Type (3-factor PCC, 4-factor PCC), By Application (Congenital and Acquired Coagulation Factor deficiency), By End User (Hospitals, Ambulatory Surgical Centers), and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Prothrombin Complex Concentrate PCC Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Prothrombin Complex Concentrate PCC market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Prothrombin Complex Concentrate PCC market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Prothrombin Complex Concentrate PCC Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Prothrombin Complex Concentrate PCC Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Prothrombin Complex Concentrate PCC Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
Grifols SA
  
CSL Behring
  
Octapharma AG
  
Sanquin
  
Shire
  
Kedrion S.p.A
  
China Biologic Products Holdings, Inc.
  
Other players

Key Industry Developments

In August 2018, Grifols S.A acquired 24 plasma donation centers in the U.S., which were previously operated by Biotest Pharmaceuticals Corp., a subsidiary owned by Biotest US Corporation. As a result, Grifols now own 249 plasma donation centers to increase the supply of plasma proteins to be used for therapeutic purposes.

In June 2017, CSL Limited acquired Wuhan Zhong Yuan Rui De Biological, a Chinese plasma fractionator, which provides it a strategic position in the plasma fractionation market in China. Also, CSL received approval for its leading PCC brand Kcentra in Japan in 2017.

In October 2017, China Biologic Products Holdings, Inc. acquired Tianxinfu Medical Appliance Co., Ltd., a medical devices company, which will enable the company to launch its PCC product at neurosurgical and another surgical department which were previously covered by Tianxinfu.